🔗 Share this article

While the US continues making historic adjustments to its vaccine guidelines, one figure appears in a surprising turn: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who rose to prominence by casting doubt on COVID-19 shots in the pandemic and has focused upon potential deaths following Covid immunization in her short time at the Food and Drug Administration.

Proposed Overhauls to Pediatric Vaccine Program

Public health authorities were set to announce major revisions to the childhood vaccine schedule recently, bringing the US with Denmark’s immunization schedule, it is understood – a significant shift that would put the US out of alignment with much of the international standard with little proof for benefit. The planned update has been pushed back until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is scheduled to address the audience at the gathering. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth individual to head the center this year.

A New Direction at the Regulatory Body

The acting appointment may indicate a tighter collaboration between the drug and biologics divisions as Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a renewed priority upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for halting specific childhood vaccine recommendations in the US in order to be more like Denmark, a country with comprehensive healthcare and a population about the size of Wisconsin’s.

So far comments, she has kept her attention on immunizations – usually the domain of Prasad, director of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Expertise

Høeg has little discernible track record in medication creation, regulation or management, which has been typical for past leaders of the biologics center. She has served at the FDA as a top consultant to the commissioner and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for leading the CDER, remarked Jonathan Howard. “She lacks experience running a scientific study. She is not versed in managing a large organization. She is not an expert in industry regulation.”

Past commissioners of CBER would “grasp laws and regulations and the science of drug development”, commented Dr. Janet Woodcock. “Objectively, she doesn’t have the type of experience that prior appointees who headed the center have had.”

The drug center has an immense range of responsibilities at the agency, the former commissioner pointed out.

“Everybody just focuses on the innovative therapies, but the generic program clears a multitude of off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and so forth, and all of those have to be supervised,” Dr. Woodcock noted. “The thing you overlook, that is the part that I always told people is going to bite you.”

There is also, a major leadership element to the job, which oversees over 5,000 employees. “It is a massive administrative position, if you perform it correctly,” Woodcock said.

Official Statement and Controversial Programs

In response to inquiries about Dr. Høeg's credentials and whether this assignment represents greater collaboration among regulatory chiefs on vaccines, a press secretary stated that the “concerns stem from flawed premises”.

“Her experience is consistent with the functions of her role,” the representative said, pointing to the period Høeg spent advising the agency head on “drug safety and regulatory science, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the commissioner’s new priority voucher program, a disputed one-day therapy clearance system that reportedly worried her preceding directors. “By what process are these drugs being selected for this expedited pathway? Who takes the choices?” Dr. Howard asked. “There’s a lot of secrecy occurring at the FDA right now.”

Overall, he stated, “the agency appears to be shifting towards less stringent oversight of all drugs, aside from vaccines.”

Documented Track Record on Vaccines

Concerning vaccines, Høeg has a clearer, if concerning, track record, some experts said. She published a research paper using unconfirmed volunteer-provided data to determine the rate of myocarditis following COVID-19 vaccination. She consulted for the Florida top health official Joseph Ladapo, who was said to have changed statistics to imply Covid vaccinations are more dangerous than they are.

Part of her “policy goals” for the current government featured changing rules for novel immunizations and ending “non-essential” vaccines, she stated post-election on a online show. At the agency, Høeg has according to sources proposed barring adolescent males from obtaining COVID-19 vaccines.

“She’s an complete ideologue who starts off with her preconceived notions and tailors the evidence to accommodate the data in a very disingenuous, dishonest fashion,” Dr. Howard said.

Gaining Influence and a “Campaign of Retribution”

Høeg became part of fellow skeptics, {like|